Is anyone making bonus on Kyprolis?

Discussion in 'Amgen' started by anonymous, Aug 15, 2016 at 11:13 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Burning buikding
     

  2. anonymous

    anonymous Guest

    Great drug but crazy goals = zero bonus and reps quitting
     
  3. anonymous

    anonymous Guest

    LAURA BRAND WANTS YOU ALL TO QUIT SO SHE CAN HIRE EXPERIENCED BCG CONSULTANTS TO SELL KYPROLIS. THEY WILL ALL PUT YOU REPS TO SHAME!
     
  4. anonymous

    anonymous Guest

    the funny thing is that us Kyprolis reps making zero bonus can now work 10 hrs a week like blue/orange reps- why even try?
    Sad thing is that it is hurting patients-
     
  5. anonymous

    anonymous Guest

    This why we Orange and Blue will get your product you lazy bums. We will show you how to dominate in oncology.
     
  6. anonymous

    anonymous Guest

    Really, why didn't you do that with Vectibix and T-Vec. The Onyx folks actually outsold the Amgen territories with Vectibix. Oh you thought we forgot about that didn't you. Amgen OBU = primary care losers.
     
  7. anonymous

    anonymous Guest

     
  8. anonymous

    anonymous Guest


    and guess what we on the Neulasta side are getting our S1 goals adjusted so that we make money! look who Amgen really cares about. We are the ones to make money and work 4 hours a day!!!!!
     
  9. anonymous

    anonymous Guest

    Dummy...we're all Amgen now. There are almost no legacy Onyx reps left.
     
  10. anonymous

    anonymous Guest

    They don't get it
     
  11. anonymous

    anonymous Guest

    I am having so much fun talking about cardiac and aneurysm side effects with Kyprolis. With no bonus and unatrainable goals, what else is their to talk about! Ha!! F U Amgen!!
     
  12. anonymous

    anonymous Guest

    I do the same too. I am waiting for another Clovis build up. I heard Array Biopharma will be looking soon too. I am going to FUCK Kyprolis by talking about the safety considerations but will forget about efficacy.
     
  13. anonymous

    anonymous Guest

    I am my way out by working only a few hours a day. When I do go out I talk about the safety issues of kyprolis but never mention the overall
    Survival benefit. In fact some of my doctors have switched patients back to velcade or to Ninlaro. Darzelex is killing it and the rep told me they are hiring in territory. It may be big pharma but at least I get paid and the drug is better than kyprolis. F Amgen!
     
  14. anonymous

    anonymous Guest

    Let's see how Brian Heath and Laura Brand try and motivate me. Laura will replace us with fancy MBAs with no oncology Doctor relationships. Watch the brand just die.
     
  15. anonymous

    anonymous Guest

    To all my fellow Onyx people left and those new Amgen Kyprolis reps that are not hitting goal or making money. I hereby declare the week of September 6th, national cardiac and aneurysm week for Kyprolis. Let's freakin' kill this brand and get the heck out of here. Please pledge that you will only speak of the warning letter and cardiac this week and no efficacy at all! Who is with me?
     
  16. Brian Heath

    Brian Heath Guest

    Try this and I will have Amgen Repata or Enbrel reps replacing you. F with my bonus, I will F with your employment.
     
  17. anonymous

    anonymous Guest

    We the Repatha reps would gladly take kyprolis. At least it has some access.
     
  18. anonymous

    anonymous Guest


    HAHAHA Amgen's plan is to throw PCP reps on it's only therapeutic oncology product! No one Amgen OBU is the biggest joke.

    Repatha reps can't sell in CV and now they think they can walk into oncology. What a joke.
     
  19. anonymous

    anonymous Guest

    So are they adjusting quotas or what? Funny we don't even have official numbers yet but we all know we're screwed
     
  20. anonymous

    anonymous Guest

    No adjustments. Amgen wants to keep quota high to get rid of the low performing reps. Amgen needs kyprolis to grow so quota will not be adjusted. Amgen also does not want to payout reps for trying. They want reps who exceed quota. They are willing to transfer reps from other BUs to oncology to fill the void and give them a crack at hitting the target quota.